How to take AOD-9604: dose, timing, and the honest evidence

Last updated 2026-07-24

What is AOD-9604 and how is it supposed to work?

AOD-9604 is a synthetic fragment of human growth hormone. Specifically, it's the region of the hGH molecule (amino acids 176-191) that researchers isolated because it seemed responsible for fat metabolism effects without the growth-promoting effects of full-length hGH. The idea, going back to work summarized in a 2004 review, was to keep the lipolytic signal and drop the parts of hGH that raise blood sugar and drive tissue growth ^[1]. That's a genuinely clever piece of chemistry. Cutting a hormone down to the fragment that does the one thing you want is a reasonable drug design strategy, and it's been tried with other hormone fragments too. The problem is that a clever mechanism doesn't guarantee a clinical result. A 2006 survey of obesity drugs in clinical development lists AOD-9604 among the compounds being tested for fat-loss effects during that era, alongside other mechanisms being explored at the time ^[2]. It was a real candidate in a real pipeline, not a fringe idea invented for the supplement market.

How to take AOD-9604: typical dose, route, and timing

There is no FDA-approved dosing regimen for AOD-9604 because there is no FDA-approved AOD-9604 product. You won't find it in the Drugs@FDA database ^[3]. Everything below reflects how it's discussed in research-use and compounding contexts, not an approved label. Common self-administration protocols use 250 to 500 mcg injected subcutaneously once per day, usually in the abdomen or upper thigh, five to seven days a week. Most people who follow this route inject fasted, either first thing in the morning before eating or before bed, on the theory that insulin blunts any lipolytic signaling. Whether that theory holds up in humans at this dose is untested; it's inference borrowed from growth hormone physiology, not a finding specific to AOD-9604. A sample weekly layout looks like this:

For the actual reconstitution steps (how much bacteriostatic water to add, how to draw the dose into an insulin syringe, how to store it), see aod 9604 how to reconstitute. If you want a fuller breakdown of dose ranges and how people adjust them by bodyweight, the aod 9604 dosage guide and the aod 9604 dosage calculator go deeper than this article needs to.

Does the human trial data actually support AOD-9604 for fat loss?

This is the part that gets buried by sellers, so it goes up front here: the human obesity trial program for AOD-9604 did not produce weight-loss results that clearly separated from placebo. That's the central finding a reader needs before anything about dosing matters. The compound went through a clinical trial program summarized across several 'Gateways to clinical trials' reports published in Methods and Findings in Experimental and Clinical Pharmacology in 2003 and 2005, which log AOD-9604 among drug candidates moving through development-stage trials during that period ^[4][5][6]. These reports are pharmaceutical-industry trial trackers, not detailed efficacy papers, but they confirm AOD-9604 reached human testing under a real development program, sponsored at the time by Metabolic Pharmaceuticals in Australia. The 2004 review in Current Opinion in Investigational Drugs describes AOD-9604's proposed metabolic mechanism and its position in that development pipeline ^[1]. What none of the available literature shows is a clean, replicated, placebo-beating weight-loss signal in humans at a scale that would justify approval. The compound did not go on to FDA approval, and it is not listed in Drugs@FDA today ^[3]. That absence is itself data. Drugs with strong efficacy signals and manageable safety profiles get pushed through to approval; drugs with weak or inconsistent signals tend to stall, and that's what happened here. If you're comparing AOD-9604 against options with a stronger evidence base for weight loss, GLP-1 receptor agonists (semaglutide, tirzepatide) have multiple large randomized controlled trials published in flagship journals showing double-digit percentage body weight reduction. AOD-9604 has nothing comparable. That's not a knock on the mechanism being interesting; it's a statement about what has and hasn't been demonstrated in controlled human trials.

Is AOD-9604 legal to buy and use?

AOD-9604 is not an FDA-approved drug, and it does not appear on either FDA bulk drug substance list that governs what compounding pharmacies can legally use. The 503A Bulks List, at 21 CFR 216.23, and the 503B Bulks List, at 21 CFR 216.24, are the two lists that determine what a compounding pharmacy may legally compound from bulk substance under sections 503A and 503B of the Food, Drug and Cosmetic Act ^[7][8]. AOD-9604 is not on either. FDA also maintains a running list of bulk substances nominated for compounding consideration, and its bulk drug substance guidance for 503A compounding explains the review process a substance goes through before it can be added ^[9][10]. Nomination is not approval. A substance sitting on the nominated list, or being sold by a research chemical vendor, does not mean it has cleared FDA's compounding safety review. Separately, 21 U.S.C. 353a is the statute that defines what pharmacy compounding is allowed to do under federal law, and 21 CFR 201.128 defines 'intended use', which is the legal hook FDA uses to determine whether a product is being marketed as a drug ^[11][12]. Anything sold as 'not for human consumption' while being discussed for injection into humans sits in a legal and practical gray zone that a reader should understand before buying.

What does AOD-9604 do to your body, and what are the side effects?

Because there's no large, well-controlled published safety trial specific to AOD-9604 at consumer-market doses, most of what's known comes from its mechanistic relationship to hGH fragments and from general peptide-safety literature, not from a dedicated long-term human safety study of AOD-9604 itself. A 2026 review on peptide therapies in orthopaedics covers safety and application questions across a range of peptides used off-label, including growth-hormone-related fragments, and flags the general gap between mechanistic promise and clinical validation that applies broadly to this drug class ^[13]. A related 2026 review in Sports Medicine specifically addresses the safety and efficacy record of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, again pointing out that many peptides marketed in this space lack the controlled trial data that would normally support safety claims ^[14]. Commonly reported issues with self-administered AOD-9604 are injection site redness, mild swelling, and occasional headache, based on user reports rather than published trial data. For a fuller rundown of what's documented and what's anecdotal, see aod 9604 peptide side effects.

Will AOD-9604 show up on a drug test or violate anti-doping rules?

AOD-9604 is banned by the World Anti-Doping Agency as part of its growth hormone and growth hormone releasing factor category, and testing labs have specifically studied whether it interferes with existing hGH detection assays. A 2013 study in Drug Testing and Analysis found that AOD-9604 does not influence the WADA hGH isoform immunoassay, meaning it doesn't mask or confound the standard test used to detect hGH doping ^[15]. That finding matters for two reasons. First, it tells you AOD-9604 doesn't hide other hGH use from testers. Second, it implies anti-doping labs have their own separate detection methods aimed at AOD-9604 directly, rather than relying on it slipping through the standard hGH test. Broader analytical chemistry literature backs this up. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis reviews methods for detecting emerging and non-approved therapeutics, including small peptides like AOD-9604, in doping control samples ^[16]. A 2014 review in Expert Review of Proteomics covers detection strategies specifically for peptidic drugs, drug candidates, and their analogs in sports doping ^[17]. And a 2016 method paper in the Journal of Separation Science describes a direct urine injection, liquid chromatography, and ion mobility mass spectrometry approach built specifically to screen for peptides under 2 kDa, a category that includes AOD-9604 ^[18]. If you compete in any WADA-governed or major professional sport, treat AOD-9604 as detectable and banned, full stop.

How long does it take to see results, and how do you know if it's working?

There is no published human trial establishing a reliable timeframe for fat-loss effects from AOD-9604, because there's no published human trial that clearly demonstrated the fat-loss effect in the first place beyond the mechanistic and early-phase development work already discussed ^[1][4][5][6]. Anyone giving you a specific week-by-week results timeline is speculating, not quoting data. If you decide to try it anyway, track objective measurements, more than how your clothes feel. Bodyweight at the same time of day, waist circumference at the same landmark point on your body, and ideally a DEXA scan or comparable body composition test before starting and again at 8-12 weeks give you something closer to real signal than the mirror does. Because there's no confirmed dose-response relationship in humans, there's also no confirmed 'if it's working, you'll notice by week X' rule to hang your judgment on.

How does AOD-9604 compare to other fat-loss peptides and drugs?

The honest takeaway from this table is that AOD-9604 sits in the same bucket as many other unapproved peptides discussed in the 2026 orthopaedics and sports medicine reviews: interesting mechanism, real development history, but no strong confirmed human efficacy signal for the outcome people actually want (visible, reliable fat loss) ^[13][14]. If your priority is the best-supported option for weight loss specifically, GLP-1 drugs have a much deeper trial record. If you're specifically interested in the fragment-of-hGH mechanism for research purposes, aod 9604 peptide covers that background in more depth.

Where do people source AOD-9604, and what should you check before buying?

Because AOD-9604 isn't FDA-approved and isn't on FDA's compounding bulk lists, it's typically sold either as a 'research chemical' (labeled not for human use) or through compounding pharmacies operating in a gray area relative to 503A rules ^[7][8][11]. Quality control varies enormously between vendors. There's no FDA oversight equivalent to what an approved drug gets, so the burden of checking quality falls entirely on the buyer. If you're going to source it at all, look for a third-party certificate of analysis for the specific batch (not a generic COA), confirmation of peptide purity and identity by mass spectrometry, and a supplier that's transparent about where the material is manufactured. Provider-reviewed sourcing routes that name their fulfilling pharmacy partner and show batch-specific testing are a meaningfully lower-risk option than an anonymous online storefront with no verifiable lab documentation. AOD-9604 Co's provider-reviewed sourcing guide, aod 9604 peptide for sale, walks through what to check before you buy, and does not compound or manufacture anything itself; it points you to reviewed fulfillment routes rather than selling directly.

Who should not take AOD-9604?

Because there's no dedicated large-scale human safety trial for AOD-9604 at consumer doses, the honest answer is that nobody has a well-characterized safety profile to rely on, which itself is a reason for caution in several groups. Pregnant or breastfeeding people, anyone with active cancer or a history of hormone-sensitive cancer, people with poorly controlled diabetes, and anyone under 18 should not use it outside a supervised clinical trial setting, given the total absence of controlled safety data in these populations. Anyone competing in WADA-governed or professional sports should also avoid it entirely, since it's a banned substance and detectable by dedicated assays even though it doesn't interfere with the standard hGH immunoassay ^{[15][16][17][18]}.

Frequently asked questions

What is the standard AOD-9604 dosage for fat loss?

Most self-administration protocols use 250 to 500 mcg subcutaneously once daily, often fasted. This is not an FDA-approved dose; there's no approved label because there's no approved product. It reflects common practice in research and compounding contexts, not a confirmed clinical dose-response finding.

What time of day should you inject AOD-9604?

Most protocols call for injecting fasted, either first thing in the morning or before bed, based on the theory that insulin blunts lipolytic signaling. This timing logic comes from general growth hormone physiology, not from a human trial that tested AOD-9604 timing specifically.

Does AOD-9604 actually cause fat loss in humans?

The published record shows AOD-9604 entered human clinical trials for obesity, but no available data shows a weight-loss effect that clearly beat placebo. It never reached FDA approval and isn't in the Drugs@FDA database, which is consistent with a weak or inconclusive efficacy signal in trials.

Is AOD-9604 banned in sports?

Yes. It falls under WADA's growth hormone and growth hormone releasing factor category. A 2013 study confirmed AOD-9604 doesn't interfere with the standard WADA hGH immunoassay, meaning separate detection methods exist specifically for it, so treat it as testable and banned.

Can you legally buy AOD-9604 in the US?

It's not on FDA's 503A or 503B bulk drug substance lists that govern legal compounding, and it's not an FDA-approved drug. It's typically sold as a research chemical or through gray-area compounding channels, which puts it in an unclear legal space for human use.

How long before you see results from AOD-9604?

There's no published trial establishing a reliable results timeline, because no published trial clearly established the fat-loss effect itself. Anyone quoting a specific week-by-week timeline is speculating rather than citing data specific to this compound.

What are the side effects of AOD-9604?

Commonly reported issues are injection site redness, mild swelling, and occasional headache, based on user reports rather than a large controlled safety trial. No dedicated long-term human safety study of AOD-9604 at consumer doses has been published.

How is AOD-9604 different from full hGH?

AOD-9604 is a fragment representing amino acids 176-191 of the hGH molecule, isolated because that region was linked to fat metabolism effects while lacking the growth-promoting activity of the full hormone. That's the design rationale; it doesn't mean the fat-metabolism effect was confirmed at the clinical trial level in humans.

Should you cycle AOD-9604, or take it continuously?

There's no published human trial defining an optimal cycle length for AOD-9604, so any cycling schedule you see online is based on general peptide practice, not compound-specific data. Given the weak efficacy record, there's no strong evidence-based reason to prefer one cycling pattern over another.

Is AOD-9604 better than semaglutide or tirzepatide for weight loss?

No. GLP-1 drugs like semaglutide and tirzepatide have multiple large randomized controlled trials showing substantial body weight reduction and are FDA-approved. AOD-9604 has a much thinner human evidence base, with no clear placebo-beating weight-loss result published, and no FDA approval.

Can AOD-9604 be detected in a drug test?

Yes, through dedicated mass spectrometry-based methods built for small peptides, including approaches described in 2014 and 2016 analytical chemistry papers. It does not interfere with the standard WADA hGH immunoassay, so it doesn't help mask other hGH use either.

Do you need a prescription for AOD-9604?

It's not an FDA-approved drug, so there's no standard prescription pathway for it. It's typically obtained through compounding pharmacies operating outside the FDA's approved bulk substance lists, or sold as a labeled research chemical, both of which carry legal and quality uncertainty.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): Describes AOD-9604's proposed fat-metabolism mechanism as an hGH fragment and its position in obesity drug development.
2. PubMed, Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews (2026): Reviews therapeutic peptide applications and safety/challenges in orthopaedics, including growth-hormone-related fragments.
3. PubMed, Sports Medicine (2026): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance.
4. PubMed, Drug Testing and Analysis (2013): Found AOD-9604 does not influence the WADA hGH isoform immunoassay.
5. PubMed, Current Opinion in Investigational Drugs (2006): Lists AOD-9604 among obesity drugs in clinical development during that period.
6. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Reviews analytical detection approaches for emerging and non-approved therapeutics including small peptides in doping controls.
7. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Logs AOD-9604 among compounds moving through development-stage clinical trials in 2003.
8. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Additional trial-tracker entry documenting AOD-9604's clinical development status in 2003.
9. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): Trial-tracker entry documenting AOD-9604's continued clinical development status in 2005.
10. PubMed, Expert Review of Proteomics (2014): Reviews detection strategies for peptidic drugs and analogs, including AOD-9604, in sports doping.
11. PubMed, Journal of Separation Science (2016): Describes a direct urine injection LC-ion mobility mass spectrometry method for screening peptides under 2 kDa.
12. FDA, Drugs@FDA database: AOD-9604 does not appear as an FDA-approved drug product in this database.
13. eCFR, 21 CFR 216.23 (503A Bulks List): AOD-9604 is not included on the FDA's 503A bulk drug substances list for compounding.
14. eCFR, 21 CFR 216.24 (503B Bulks List): AOD-9604 is not included on the FDA's 503B bulk drug substances list for outsourcing facility compounding.
15. FDA, Bulk drug substances used in compounding under section 503A: Explains FDA's review process for adding bulk substances to the 503A compounding list.
16. FDA, Bulk drug substances nominated for use in compounding (current list): Lists substances nominated for compounding consideration, distinct from substances actually approved for compounding.
17. Cornell Law, 21 U.S.C. 353a (pharmacy compounding): Defines the federal statutory conditions under which pharmacy compounding is permitted.
18. eCFR, 21 CFR 201.128 (meaning of intended uses): Defines 'intended use,' the legal standard FDA applies to determine if a product is being marketed as a drug.